Design and Synthesis of a PSMA Inhibitor–Doxorubicin Conjugate for Targeted Prostate Cancer Therapy
S. Jayaprakash,Xinning Wang,W. Heston,A. Kozikowski
DOI: https://doi.org/10.1002/cmdc.200500044
IF: 3.54
2006-03-13
ChemMedChem
Abstract:Prostate cancer is the most commonly diagnosed cancer and the second leading cause of death in men in the United States after lung cancer. It is estimated that prostate cancer affects approximately 180000 and kills 40000 men in the United States each year. As long as the cancer is confined to the prostate, it can be successfully controlled by surgery or radiation, but there is little effective treatment available for the metastatic disease, particularly if androgen-deprivation therapy fails. 3] Advances in our understanding of tumor immunology have, however, led to new approaches for treatment of prostate and other cancers, including tumor antigen-specific immunotherapy. Several prostate antigens have now been identified that are attractive candidates for both prostate-tumor imaging and therapy. One of the most interesting among these is the prostate-specific membrane antigen (PSMA). PSMA is considerably upregulated in prostate cancers, metastatic disease, and in hormone-refractory prostate cancers. 7] Capromab pendetide (ProstaScint) is a commercially available monoclonal antibody in clinical use for detecting prostate cancer, but it has been cited for complexities associated with its administration and the interpretation of the images obtained. PSMA is a 100 kDa, type II membrane glycoprotein highly expressed by all prostate cancers as well as by nonprostatic tumor neovasculature and the vascular endothelium of virtually all solid sarcoma and carcinoma tumors. PSMA is highly homologous to the neuropeptidase NAALADase (GCP II) that releases the neurotransmitter glutamate from the neuronal peptide NAAG (N-acetyl-l-aspartyl-l-glutamate). PSMA also exhibits folate hydrolase activity whereby it cleaves terminal glutamates from g-linked polyglutamates. A 3.5 < resolution crystal structure of the PSMA ectodomain has been disclosed recently. The homodimer contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding arginine patch, which is similar to our previously modeled three-dimensional structure of the GCP II extracellular domain obtained through homology-based modeling methods. Based upon mechanistic considerations together with the modeling studies, we have developed an array of potent, urea-based inhibitors of NAAG peptidase/PSMA. Since PSMA is significantly upregulated in prostate cancer and metastasis, and is strongly expressed in the neovasculature of solid tumors, we have explored the use of our designed small-molecule inhibitors as PET imaging agents. As these imaging applications proved successful, we turned our attention to the possibility of using these same PSMA inhibitors for the targeting of anticancer drugs to prostate cancer cells. Anticancer drugs, including doxorubicin and others, have limited utility in prostate cancer therapy due to their poor target selectivity and systemic toxicities, such as cardiotoxicity and immunosuppression. Targeted therapy for cancer offers potential improvements over existing chemotherapy regimens since the drug is delivered preferentially to the cancer tissue and side effects can be minimized. Research in this area has produced several cytotoxic conjugates with improved selectivity and drug effects. We sought to synthesize a conjugate between one of our PSMA inhibitors and the anticancer drug doxorubicin in order to test whether such a hybrid molecule would lead to a drug with an improved therapeutic index. We report here the design, synthesis, and biological activity of PSMA–doxorubicin conjugate 1 targeted for prostate cancer therapy. In the design of the PSMA–doxorubicin conjugate, it was important to define the optimal sites on both the doxorubicin and the PSMA inhibitor for attachment of a linker. It is known that acylation of the amino group present in the pyranose ring of doxorubicin results in a decrease in the cytotoxicity of this drug. Our previous SAR work on the NAAG peptidase inhibitors had revealed that the urea formed between glutamate and a variety of phenylalanine derivatives containing diverse substituents on the para-position of the aromatic ring serve as potent (nm) peptidase inhibitors. We elected to join a ureabased PSMA inhibitor made up of p-aminophenylalanine through a glutaric acid linker to doxorubicin (Scheme 1). The amino groups present in these two moieties thus became the key connection points. In pursuing this approach, we imagined that the PSMA inhibitor would serve to target the doxorubicin to the prostate cancer cells. Once it was localized there and internalized, other amidase/peptidase activities (e.g. , PSA, but not the extracellular PSMA, as this would be inhibited by the bioconjugate) would free the doxorubicin. In support of the possibility for internalization, we refer to the recent article by Langer et al. that demonstrates that a nanoparticle–aptamer bioconjugate comprising RNA aptamers that target PSMA can be internalized into LNCaP cells after a 2 h incubation period. Moreover, a previous report has revealed an antibody-mediated enhancement in the rate of PSMA endocytosis in LNCaP cells. With the above considerations in mind, we began the synthesis of our designed, small-molecule–PSMA inhibitor-based bioconjugate with the preparation of the urea derivative 6, as shown in Scheme 2. [a] Dr. S. Jayaprakash, Prof. A. P. Kozikowski Drug Discovery Program Department of Medicinal Chemistry and Pharmacognosy 833 South Wood Street, Chicago, IL 60612 (USA) Fax: (1) 312-996-7107 E-mail : kozikowa@uic.edu [b] Dr. X. Wang, Dr. W. D. Heston The Cleveland Clinic Foundation Department of Cancer Biology 9500 Euclid Avenue, Cleveland, OH 44195 (USA) Supporting information for this article is available on the WWW under http://www.chemmedchem.org or from the author : experimental procedures and characterization data for compounds 1, 3, 4, 6–10.